Navigation Links
OXIS International Names Former Wal-Mart Executive Ken Eaton to Board of Directors
Date:6/27/2011

BEVERLY HILLS, Calif., June 27, 2011 /PRNewswire/ -- OXIS International, Inc. (OTC Bulletin Board: OXIS; Euronext Paris: OXI) today announced that it has named former Wal-Mart executive Ken Eaton to its Board of Directors.  The Company's Board now has four members, including three independent Directors.

"I am very pleased to bring an executive of Ken's caliber to the OXIS International Board of Directors," said Anthony J. Cataldo, Chairman of OXIS International.  "Ken provides expertise in merchandising with major retailers and in worldwide marketing.  His knowledge and industry relationships will prove invaluable in developing and executing our long term growth strategy."

Mr. Eaton has more than 25 years of operational and merchandising experience, including 20 years in management with Wal-Mart.  At Wal-Mart he served in several senior level positions, including Vice President, Divisional Merchandising Manager, and Senior Vice President, General Merchandising Manager.  Mr. Eaton was also involved in the formation of the Wal-Mart Supercenter store model, and led the formation of the company's global procurement division.

He is currently the co-founder and Executive Director of Silverlink Holdings, which operates a consumer products company with distribution in North America and Asia.

About OXIS International, Inc.

OXIS International, Inc. is a long-established but recently revitalized biotechnology Company developing multiple proprietary, natural substance-based products focused on oxidative stress and inflammation, which are associated with the negative effects of free radicals and reactive oxygen species.  The Company's consumer product portfolio includes dietary supplements and is expected ultimately to include functional foods and beverages, skin care and other personal care products, and animal health products.  Specifically, OXIS is emphasizing the unique properties of L-Ergothioneine, a highly potent, patent-protected and versatile antioxidant.  The Company has completed a strategic financing agreement with its primary product development and manufacturing partner, Gemini Pharmaceuticals, launched its first product, ErgoFlex for joint pain relief and overall joint health, and announced a joint venture with engage:BDR, a global leader in online sales and marketing.  For more information, please visit www.oxis.com.

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may," "potential" or the negative of those words or other similar expressions words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risks and uncertainties inherent in our business, including, without limitation the risks of obtaining possibly required regulatory approvals, the timing of product introductions, the level of market acceptance of and continuing demand for the Company's products, the impact of competitive products and pricing and the Company's ability to obtain additional financing to support its operations. We refer you to the risks and factors detailed from time to time in the Company's Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q.  Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company anticipates that subsequent events and developments may cause its views to change, and the Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.


'/>"/>
SOURCE OXIS International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellular Dynamics International Unlocks the Potential of Banked Blood Samples
2. PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was
3. MAP Pharmaceuticals to Present Data on LEVADEX® at the 15th Congress of the International Headache Society
4. Asmacure Ltee to Present at the 2011 BIO Business Forum During the Annual BIO International Convention
5. Shenzhen Wuzhou Changlian International Trading Co. Establishes Relationship with Hospital in Africa
6. International Drug & Explosives Detection Company IDenta Corp. Announces New Representative in Japan
7. In Support of the International Day of the African Child, Roche Hosts Annual Childrens Walk
8. TPI Signs Macrolide API International Sales and Marketing Agreement
9. Mr. Charlie Alvarez Joins the Board of Sanomedics International Holdings, Inc.
10. BD and Heart to Heart International Launch Volunteer Service Trip to Help "Build Back Better" in Haiti
11. Paragon Bioservices to Partner and Exhibit at the 2011 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... -- Summary Breast cancer, a malignant neoplasm, is ... cancer in women worldwide, accounting for 16% of all ... of women diagnosed with breast cancer has increased over ... has declined due to earlier diagnosis and better treatment ... the past four decades, especially with increasing usage of ...
(Date:2/4/2016)... 2016 Frontier Pharma: Chronic Obstructive Pulmonary ... Chronic Obstructive Pulmonary Disease (COPD) ... of the airways and lungs. Persistent breathing difficulties ... disease one of the leading causes of morbidity ... world. COPD is linked to cumulative exposure to ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... US Sports ... Studio in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is ... just one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends ... water may be safer than regular municipal or well water. The recent experience with ... Sharon Kleyne, could go a long way toward increasing public acceptance of recycled waste ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... to search for and donate to Give To Cure’s campaign that is crowdfunding clinical ... lets users make and share payments through a smart device. In 2015 alone, Venmo ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point Consulting, a ... KLAS: Software & Services for HIT Implementation Support & Staffing report with an ... vendor performance by healthcare executives, managers and clinicians representing over 4,500 hospitals and ...
(Date:2/5/2016)... Georgia (PRWEB) , ... February 05, 2016 , ... Dr. ... to announce their 2nd Annual No Cost Dental Day to individuals in need. The ... The purpose of this No Cost Dental Day is to provide dental care to ...
Breaking Medicine News(10 mins):